Privium Fund Management B.V. Acquires 112,093 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Privium Fund Management B.V. increased its holdings in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 28.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 509,059 shares of the company’s stock after purchasing an additional 112,093 shares during the period. Privium Fund Management B.V.’s holdings in ALX Oncology were worth $926,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co acquired a new position in shares of ALX Oncology during the first quarter worth approximately $27,000. EntryPoint Capital LLC bought a new position in ALX Oncology during the first quarter worth $32,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in ALX Oncology by 394.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the last quarter. SG Americas Securities LLC boosted its holdings in ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in ALX Oncology in the 2nd quarter worth $63,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Stock Down 4.0 %

NASDAQ ALXO opened at $1.45 on Friday. ALX Oncology Holdings Inc. has a 1-year low of $1.34 and a 1-year high of $17.83. The company has a market capitalization of $76.37 million, a price-to-earnings ratio of -0.40 and a beta of 1.03. The stock’s 50 day moving average is $1.76 and its two-hundred day moving average is $6.03. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.20. Equities analysts forecast that ALX Oncology Holdings Inc. will post -3.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Lifesci Capital cut ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Monday, August 12th. UBS Group lowered their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $3.00 target price (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.50.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.